Joseph D. Eschweiler

Background

About Joseph D. Eschweiler

I am a Senior Scientist with deep experience in discovery and development of biologics, especially Antibody-Drug Conjugates (ADCs). My Ph.D. at University of Michigan focused on uses of Native Mass Spectrometry for studying noncovalent protien interactions, including experimental and computational data analysis tools. Iterations of this work are used extensively in the chemical biology and the biopharmaceutical industry to identify the next generation of drugs and drug-targets. During this time, I developed my public speaking skills through many deparmental seminars, conference presentations, and invited talks. In addition, I authored or contributed to 15 peer-reviewed publications, honing my scientific writing skills along the way. After joining AbbVie Analytical R&D in 2017, I focused on deep characterization and process development for Antibody-Drug Conjugates, learning the ropes of biopharmaceutical development while contributing to multiple IND/BLA submission documents and authoring a many of internal reports. In this position I gained further experience in project and people management, managing the execution of GMP stability studies and ensuring timely and careful data review. Additionally, I pioneered an analytical arm of the discovery screening funnel that ensured comprehensive chemical liability screening and appropriate remediation for all biologics before moving into clinical development. After 4 years in analytical development, I moved to AbbVie's discovery organization to pursue the next generation of Antibody-Drug conjugates for oncology indications. Working closely with biologists, I now manage 1 scientist to execute process development, quality control, documentation and delivery of hundreds of ADCs per year for preclinical studies, and communicate findings via oral and written reports. In this role I continue to leverage my analytical skills to investigate unexpected results and drive a culture of product quality.